Verastem (VSTM) Stock Forecast & Price Target

Verastem is supported by an increasingly de-risked pipeline that combines an approved RAF/MEK-FAK franchise with a high-upside KRAS G12D asset, giving the company both near-term commercial footing and longer-duration clinical optionality. The recently launched AVMAPKI FAKZYNJA in 2025 addresses a small but underserved LGSOC population of approximately 1K-2K new patients per year, while the underlying MEK/RAF biology has strong mechanistic rationale and early data suggesting improved safety and efficacy versus peer MEKi. In parallel, VS-7375 has shown competitive ORRs of 41% in PDAC, 33% in CRC, and 43% in NSCLC with favorable tolerability, and the company’s model points to peak revenue potential of as much as $979M and >$1.3B in combined worldwide revenues across indications.

Verastem is viewed negatively because its lead asset, Avmapki Fakzynja, still lacks sizable, definitive randomized data, leaving commercial traction, durable efficacy, and safety unproven. The company’s core opportunity in LGSOC is limited by a small addressable population and competitive pressure that could impair patient enrollment and market uptake, while failure of RAMP-301 could sharply reduce perceived value. Downside analysis suggests the shares could trade near the company’s net cash position with minimal pipeline value if the launch or program falters, and most expansion opportunities, including G12D, remain early stage without proof of concept.